Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eucrisa Adherence in Atopic Dermatitis
NCT03250663Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Oct 2017
- Primary completion
- Jul 2022
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AN2728 ointment vehicle in atopic dermatitis (AD) (2 arms), sponsored by Wake Forest University Health Sciences. Primary endpoint: Adherence to topical Therapy at 12 months. Started Oct 2017; status: completed.
02
Drugs
AN2728 ointment vehicle
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03250663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250663.